Femasys Inc FEMY
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if FEMY is a good fit for your portfolio.
News
-
Femasys CEO and Founder Kathy Lee-Sepsick Meets with Members of Congress to Raise Awareness of the Company and Discuss Women’s Healthcare Initiatives
-
Femasys Announces Financial Results for Year Ended December 31, 2023 and Provides Corporate Update
-
Femasys Invites Investors to View Fireside Chat Today, March 21, 2024, to Discuss the Infertility Treatment Landscape
-
Femasys Announces Positive Topline Data from Pivotal Trial for its FDA-Cleared FemaSeed® for the Treatment of Infertility
-
Femasys to Participate in Fireside Chat to Discuss the Infertility Treatment Landscape on March 21, 2024
-
Thinking about buying stock in Onespan, Avinger, Lithium Americas, Geron, or Femasys?
-
Femasys Completes the First In-Office Commercial Procedure with the FDA-Cleared FemaSeed Infertility Solution
-
Femasys’ FemaSeed FDA Clearance Brings Timely Access to a First-Line Infertility Treatment Option as an Alternative to IVF
Trading Information
- Previous Close Price
- $1.27
- Day Range
- $1.25–1.34
- 52-Week Range
- $0.25–4.75
- Bid/Ask
- $1.32 / $1.37
- Market Cap
- $29.17 Mil
- Volume/Avg
- 39 / 746,237
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 18.94
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Femasys Inc is a biomedical company focused on transforming women's healthcare by developing solutions and advancements providing clinical impact to address severely underserved areas. The company's mission is to provide women with minimally invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics.
- Sector
- Healthcare
- Industry
- Medical Instruments & Supplies
- Stock Style Box
- Small Value
- Total Number of Employees
- 34
- Website
- https://www.femasys.com
Valuation
|
Metric
|
FEMY
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 1.84 |
Price/Sales | 18.94 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
FEMY
|
|---|---|
Quick Ratio | 7.14 |
Current Ratio | 7.59 |
Interest Coverage | −87.72 |
Quick Ratio
FEMY
Profitability
|
Metric
|
FEMY
|
|---|---|
Return on Assets (Normalized) | −77.98% |
Return on Equity (Normalized) | −110.56% |
Return on Invested Capital (Normalized) | −86.90% |
Return on Assets
FEMY
Medical Instruments & Supplies Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
ISRG
| Intuitive Surgical Inc | Qyydspwbg | Nxgz | $132.7 Bil | |
BDX
| Becton Dickinson & Co | Yjlglyt | Ynbvx | $67.4 Bil | |
ALC
| Alcon Inc | Vlkyryfw | Yjtxjh | $38.8 Bil | |
RMD
| ResMed Inc | Nvkybwxld | Xkmrrb | $31.9 Bil | |
CLPBY
| Coloplast A/S ADR | Kvvnmmxxt | Ttmyz | $27.8 Bil | |
WST
| West Pharmaceutical Services Inc | Gqnkkyjsb | Cmvv | $25.9 Bil | |
BAX
| Baxter International Inc | Khdqwlpqs | Wzbxmx | $20.7 Bil | |
HOLX
| Hologic Inc | Yrygrmvw | Sfnfzx | $18.0 Bil | |
COO
| The Cooper Companies Inc | Pkbzdyx | Kwnxgt | $17.9 Bil | |
TFX
| Teleflex Inc | Nzz | Ndx | $9.8 Bil |